Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Component 1: Core Viral Hepatitis Outbreak Response and Surveillance Activities

Reporting Agency

Reporting jurisdiction	
Contact name (person completing form)	
Contact phone number (xxx-xxx-xxxx)	
Contact email address	
Additional contact name(s) (if applicable)	
Additional contact phone number(s) (xxx-xxx-xxxx)	
Additional contact email address(es)	
Date of report submission (MM/DD/YYYY)	
Reporting Period	Select one
(Complete this form with information from Reporting Period selected)	□ Year 1
Reporting Feriou Selecteur	□ Year 2
	□ Year 3
	□ Year 4
	□ Year 5

1.1—Develop, implement, and maintain plan to rapidly detect and respond to outbreaks of hepatitis A, hepatitis B, and hepatitis C

Measure 1.1.1.a

• A documented plan for responding to outbreaks of hepatitis A, hepatitis B, and hepatitis C infections

Outbreak type	Plan status	Topics covered (select all that apply)	Date plan was last reviewed (MM/DD/YYYY)
Hepatitis A	Select one	□ Community/person-to-person	>
	□ Completed	☐ Foodborne — associated with an infected food handler	>
	□ In progress	☐ Foodborne — associated with contaminated food	>
	□ Not started	□ Waterborne	>
		□ Other, specify:	>
Hepatitis B	Select one	□ Community/person-to-person	>
	□ Completed	□ Healthcare-associated	>
	□ In progress	□ Other, specify:	>
	□ Not started		
Hepatitis C	Select one	□ Community/person-to-person	>

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

	□ Healthcare-associated	
□ Comple	ted Other, specify:	>
□ In progr	ress	>
□ Not star	rted	

Measure 1.1.1.b

• CDC is notified of outbreaks within 5 business days of identifying the outbreak

Jurisdiction- assigned outbreak ID ¹	Outbreak type (select all that apply)	Date outbreak was confirmed (MM/DD/YYYY)	The outbreak was reported to CDC	The outbreak was reported to CDC but later determined not to be an outbreak
>	☐ Hepatitis A☐ Hepatitis B☐ Hepatitis C☐ Other, specify:>	>	Select one □ ≤ 5 business days after confirming outbreak □ > 5 business days after confirming outbreak □ Was not reported to CDC	Select one True (this was not an outbreak) False (this was a confirmed outbreak)
>	☐ Hepatitis A☐ Hepatitis B☐ Hepatitis C☐ Other, specify:	>	Select one □ ≤ 5 business days after confirming outbreak □ > 5 business days after confirming outbreak □ Was not reported to CDC	Select one True (this was not an outbreak) False (this was a confirmed outbreak)
>	☐ Hepatitis A☐ Hepatitis B☐ Hepatitis C☐ Other, specify:>	>	Select one □ ≤ 5 business days after confirming outbreak □ > 5 business days after confirming outbreak □ Was not reported to CDC	Select one True (this was not an outbreak) False (this was a confirmed outbreak)
>	☐ Hepatitis A☐ Hepatitis B☐ Hepatitis C☐ Other, specify: >	>	Select one □ ≤ 5 business days after confirming outbreak □ > 5 business days after confirming outbreak □ Was not reported to CDC	Select one True (this was not an outbreak) False (this was a confirmed outbreak)
>	☐ Hepatitis A☐ Hepatitis B☐ Hepatitis C☐ Other, specify:>	>	Select one □ ≤ 5 business days after confirming outbreak □ > 5 business days after confirming outbreak □ Was not reported to CDC	Select one True (this was not an outbreak) False (this was a confirmed outbreak)

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

>	☐ Hepatitis A	>	Select one	Select one
	☐ Hepatitis B		□ ≤ 5 business days after	□ True (this was not an
	□ Hepatitis C		confirming outbreak	outbreak)
	□ Other, specify:		□ > 5 business days after	□ False (this was a
	S other, speeny.		confirming outbreak	confirmed outbreak)
			☐ Was not reported to CDC	

Measure 1.1.1.c

• CDC is notified of all cases associated with an outbreak within 30 days of case investigation start date

For the purposes of this form, is 'Case date' being used?	e investigation start	Select one ☐ Yes
		□ No
If not, please indicate what your health department is using.		

Jurisdiction- assigned outbreak ID (corresponding to IDs from 1.1.1.b)	Number of outbreak-associated cases	Number of outbreak-associated cases reported to CDC within 30 days of case investigation start date (as determined for each case)
>	Hepatitis A:	Hepatitis A:
	Hepatitis B:	Hepatitis B:
	Hepatitis C:	Hepatitis C:
	Other (specified above):	Other (specified above):
>	Hepatitis A:	Hepatitis A:
	Hepatitis B:	Hepatitis B:
	Hepatitis C:	Hepatitis C:
	Other (specified above):	Other (specified above):
>	Hepatitis A:	Hepatitis A:
	Hepatitis B:	Hepatitis B:
	Hepatitis C:	Hepatitis C:
	Other (specified above):	Other (specified above):
>	Hepatitis A:	Hepatitis A:
	Hepatitis B:	Hepatitis B:
	Hepatitis C:	Hepatitis C:
	Other (specified above):	Other (specified above):
>	Hepatitis A:	Hepatitis A:
	Hepatitis B:	Hepatitis B:
	Hepatitis C:	Hepatitis C:
	Other (specified above):	Other (specified above):

¹ A jurisdiction-assigned unique name or identifier for an identified outbreak. For jurisdictions reporting via HL7, this is PHIN variable code=INV151 and data element identifier=77981-9.

Annual Performance Report—Component 1
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

>	Hepatitis A:	Hepatitis A:	
	Hepatitis B:	Hepatitis B:	
	Hepatitis C:	Hepatitis C:	
	Other (specified above):	Other (specified above):	
Use this space			
if needed			
to provide			
additional			
information			
related to			
Section 1.1			

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

1.2—Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for hepatitis A, acute hepatitis B, and acute and chronic hepatitis C

Measure 1.2.1.a

 Jurisdiction receives reporting of all (positive/detectable, negative/undetectable) HBV DNA and HCV RNA results at the state or local health department

Are negative hepatitis B surface antigen (sAg) results	Select one
currently reportable in your jurisdiction?	□ Yes, <u>all</u> negative lab results are reportable
	☐ Yes, some negative lab results are reportable
	Specify:
	□ No
Are negative hepatitis B sAg results currently received by	Select one
your health department?	☐ Yes, <u>all</u> negative lab results are received by the health department (complete reporting)
	☐ Yes, <u>some</u> negative lab results are received by the health department (incomplete reporting)
	Specify:
	□ No
If "Yes, all" what was the first <u>full</u> reporting year that <u>all</u>	
negative hepatitis B sAg results were available in your jurisdiction?	Year:
Are negative HBV DNA results currently reportable in your	Select one
jurisdiction?	□ Yes, <u>all</u> negative lab results are reportable
	□ Yes, <u>some</u> negative lab results are reportable
	Specify:
	□ No
Are negative HBV DNA results currently received by your	Select one
health department?	☐ Yes, <u>all</u> negative lab results are received by the health department (complete reporting)
	☐ Yes, <u>some</u> negative lab results are received by the health department (incomplete
	reporting)
	Specify:
16 "Variable Book and the Control Book and the Cont	□ No
If "Yes, all," what was the first <u>full</u> reporting year that <u>all</u> negative HBV DNA results were available in your jurisdiction?	Year:

Annual Performance Report—Component 1
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Are negative hepatitis C antibody (anti-HCV) results	Select one
currently reportable in your jurisdiction?	□ Yes, <u>all</u> negative lab results are reportable
	□ Yes, <u>some</u> negative lab results are reportable
	Specify:
	□ No
Are negative anti-HCV results currently received by your	Select one
health department?	☐ Yes, <u>all</u> negative lab results are received by the health department (complete reporting)
	☐ Yes, <u>some</u> negative lab results are received by the health department (incomplete reporting)
	Specify:
	□ No
If "Yes, all," what was the first <u>full</u> reporting year that <u>all</u> negative anti-HCV results were available in your jurisdiction?	Year:
Are negative / undetectable HCV RNA results currently	Select one
reportable in your jurisdiction?	□ Yes, <u>all</u> negative lab results are reportable
	☐ Yes, <u>some</u> negative lab results are reportable
	Specify:
	□ No
Are negative / undetectable HCV RNA results currently	Select one
received by your health department?	☐ Yes, <u>all</u> negative lab results are received by the health department (complete reporting)
	☐ Yes, some negative lab results are received by the health department (incomplete reporting)
	Specify:
	□ No
If "Yes, all," what was the first <u>full</u> reporting year that <u>all</u> negative HCV RNA results were available in your jurisdiction?	Year:

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Measures 1.2.2.a - 1.2.2.c, 1.2.3.a

- Laboratories that perform viral hepatitis-related testing for the jurisdiction report a minimum of 95% of viral hepatitis-related test results to the state or local health department
- A minimum of 85% of viral hepatitis lab results are entered into the jurisdiction's viral hepatitis surveillance database within 60 days of specimen collection date
- A minimum of 90% of case reports of hepatitis A, acute hepatitis B, and acute hepatitis C are submitted to CDC by the health department within 90 days of case investigation start date
- A minimum of 90% of case reports of chronic hepatitis C are submitted to CDC by the health department within 90 days of case investigation start date

Have you identified all laboratories that perform viral hepatitis-related testing for your	Select one
jurisdiction?	□ Completed
	□ In progress
	□ Not started
If yes, what percent of these laboratories reported viral hepatitis-related test results	Number:
during this reporting period?	Total:
	%:
	□ Unknown

During this reporting period:	
What percent of your viral hepatitis lab results were entered into your viral hepatitis	Number:
surveillance database within 60 days of specimen collection date?	Total:
	%:
	□ Unknown
What percent of your <u>hepatitis A</u> case reports were submitted to CDC within 90 days of	Number:
case investigation start date?	Total:
	%:
	□ Unknown
What percent of your <u>acute hepatitis B</u> case reports were submitted to CDC within 90	Number:
days of case investigation start date?	Total:
	%:
	□ Unknown
What percent of your <u>acute hepatitis C</u> case reports were submitted to CDC within 90	Number:
days of case investigation start date?	Total:
	%:
	□ Unknown
What percent of your chronic hepatitis C case reports were submitted to CDC within 90	Number:
days of case investigation start date?	Total:
	%:
	□ Unknown

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Measures 1.2.2.d, 1.2.3.b

- Case reports of hepatitis A, acute hepatitis B, and acute hepatitis C submitted to CDC by health departments are at least 90% complete for age, gender, race/ethnicity, county of residence, and outbreak status
- A minimum of 90% of case reports of chronic hepatitis C submitted to CDC are complete for age, gender, race/ethnicity, and county of residence

	Age	Gender	Race and/or ethnicity	County of residence	Outbreak status
Hepatitis A	Number:	Number:	Number:	Number:	Number:
	Total:	Total:	Total:	Total:	Total:
	%:	%:	%:	%:	%:
Acute hepatitis B	Number:	Number:	Number:	Number:	Number:
	Total:	Total:	Total:	Total:	Total:
	%:	%:	%:	%:	%:
Acute hepatitis C	Number:	Number:	Number:	Number:	Number:
	Total:	Total:	Total:	Total:	Total:
	%:	%:	%:	%:	%:
Chronic hepatitis C	Number:	Number:	Number:	Number:	
	Total:	Total:	Total:	Total:	
	%:	%:	%:	%:	

Measure 1.2.2.e

• Case reports of hepatitis A, acute hepatitis B, and acute hepatitis C submitted to CDC by health departments are at least 70% complete for risk factors

Risk behaviors and exposures				
Hepatitis A Acute hepatitis B Acute hepatitis C				
Injection drug use	Injection drug use	Injection drug use		
Number:	Number:	Number:		
Total:	Total:	Total:		
% complete:	% complete:	% complete:		
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)		
Sexual contact	Sexual contact	Sexual contact		
Number:	Number:	Number:		
Total:	Total:	Total:		
% complete:	% complete:	% complete:		
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)		

Annual Performance Report—Component 1
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Household contact (non-sexual)	Household contact (non-sexual)	Household contact (non-sexual)
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
Other contact	Multiple sex partners	Multiple sex partners
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
Men who have sex with men	Men who have sex with men	Men who have sex with men
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
International travel	Surgery	<u>Surgery</u>
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
Homelessness/unstable housing	<u>Dialysis patient</u>	<u>Dialysis patient</u>
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
<u>Incarceration</u>	Transfusion (tissue or organ)	Transfusion (tissue or organ)
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
Non-injection drug use	<u>Needlestick</u>	<u>Needlestick</u>
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)
Drug sharing partner	Occupational exposure to blood	Occupational exposure to blood
Number:	Number:	Number:
Total:	Total:	Total:
% complete:	% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)	□ N/A (not reported)

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Drug sharing partner	Drug sharing partner
Number:	Number:
Total:	Total:
% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)
Homelessness/unstable housing	Homelessness/unstable housing
Number:	Number:
Total:	Total:
% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)
<u>Incarceration</u>	<u>Incarceration</u>
Number:	Number:
Total:	Total:
% complete:	% complete:
□ N/A (not reported)	□ N/A (not reported)
' ' '	, , ,
Non-injection drug use	Non-injection drug use
Non-injection drug use	Non-injection drug use
Non-injection drug use Number:	Non-injection drug use Number:
Number: Total:	Non-injection drug use Number: Total:
Non-injection drug use Number: Total: % complete:	Non-injection drug use Number: Total: % complete:
Non-injection drug use Number: Total: % complete: N/A (not reported)	Non-injection drug use Number: Total: % complete: N/A (not reported)
Non-injection drug use Number: Total: % complete: N/A (not reported) Tattoo receipt	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt
Non-injection drug use Number: Total: % complete: N/A (not reported) Tattoo receipt Number:	Non-injection drug use Number: Total: % complete: N/A (not reported) Tattoo receipt Number:
Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total:	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total:
Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete:	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete:
Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete: □ N/A (not reported)	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete:
Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete: □ N/A (not reported) International travel	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete:
Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete: □ N/A (not reported) International travel Number:	Non-injection drug use Number: Total: % complete: □ N/A (not reported) Tattoo receipt Number: Total: % complete:

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Measure 1.2.3.c

• A minimum of 90% of case reports of chronic hepatitis C are included in a longitudinal surveillance registry, including longitudinal detectable and undetectable HCV RNA test results

Have you developed a longitudinal surveillance registry for	Select one	
chronic hepatitis C?	□ Completed	□ Not started
	□ In progress	
What percent of your chronic hepatitis C case reports are	Number:	□ Unknown
included in your registry?	Total:	□ N/A (registry not started)
	%:	
Does your registry include longitudinal detectable and	Select one	
undetectable HCV RNA test results for the chronic hepatitis	□ Yes	□ N/A (registry not started)
C cases?	□ No	

Measures 1.2.4.a, 1.2.5.a

- Jurisdiction reports data on hepatitis C viral clearance cascade, consistent with CDC guidance
- Prepare and disseminate an annual viral hepatitis surveillance report, including data on hepatitis A, acute hepatitis B, and acute and chronic hepatitis C to support prevention programs and policies

Have you developed a hepatitis C viral clearance	Select one
cascade?	□ Completed □ Not started
	□ In progress
If hepatitis C viral clearance cascade "Completed,"	□ Date completed (MM/DD/YYYY):
please indicate when the most recent cascade was	□ Please provide URL for cascade, if available:
completed and provide the URL for—or a copy of—the cascade.	
	If URL not available, please submit a copy of the
	cascade with the APR.
	Select one
	□ Submitted □ Not submitted
Have you developed a viral hepatitis surveillance	Select one
report?	□ Completed □ Not started
	□ In progress
If viral hepatitis surveillance report "Completed,"	□ Date completed (MM/DD/YYYY):
please indicate when the most recent report was	□ Please provide URL for report, if available:
completed and provide the URL for—or a copy of—the report.	
Toporti	If URL not available, please submit a copy of the
	report with the APR.
	Select one
	□ Submitted □ Not submitted

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Use this space if needed	
to provide	
additional information	
related to Section 1.2	
Section 1.2	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

This section is to be completed in YEAR 1 ONLY

Among all the newly reported hepatitis B cases (acute and	Select one	
chronic) in 2019 among individuals ≤40 years of age, what	□ None	□ 50% - <75%
proportion had an unknown anti-HBC IgM result?	□ <25%	□ <u>></u> 75%
	□ 25% - <50%	
Among those cases that had an unknown anti-HBc IgM	Select one	
result, what proportion were investigated?	□ None	□ 50% - <75%
	□ <25%	□ <u>></u> 75%
	□ 25% - <50%	
Among all newly reported hepatitis C cases (acute and	Select one	
chronic) in 2019 among individuals ≤40 years of age, what	□ None	□ 50% - <75%
proportion of cases were investigated by a public health department?	□ <25%	□ <u>></u> 75%
acpartment.	□ 25% - <50%	

Of all of the hepatitis A, acute hepatitis B, and acute hepatitis C infections that you believe (or have estimated) occurred in your jurisdiction in 2019, what proportion do you believe were: 1) reported to the state or local health department in your jurisdiction and 2) a notification was sent to CDC?

Confirmed		Confirmed		Confirmed	
Hepatitis A		Hepatitis B, acute		Hepatitis C, acute	
Reported to	CDC was	Reported to	CDC was	Reported to	CDC was
your jurisdiction	notified	your jurisdiction	notified	your jurisdiction	notified
Select one	Select one	Select one	Select one	Select one	Select one
□ <25%	□ <25%	□ <25%	□ <25%	□ <25%	□ <25%
□ 25%-<50%	□ 25%-<50%	□ 25%-<50%	□ 25%-<50%	□ 25%-<50%	□ 25%-<50%
□ 50%-<75%	□ 50%-<75%	□ 50%-<75%	□ 50%-<75%	□ 50%-<75%	□ 50%-<75%
□ ≥75%	□ ≥75%	□ ≥75%	□ ≥75%	□ ≥75%	□ ≥75%
Please provide a brief justification for the answer you selected for each acute viral hepatitis infection in the question above.					

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Was Section 1.3 funded?	Select one	□ No NOTE: Stop here if not funded	□ Yes

1.3—Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for chronic hepatitis B and perinatal hepatitis C

Measures 1.3.1.a - 1.3.1.b, 1.3.1.d, 1.3.2.a

- By December 31st of each year, mother and child matches are ascertained from local/state health department vital records through the end of the prior year by linking all known births to mothers found in viral hepatitis surveillance data base
- A minimum of 90% of case reports of perinatal hepatitis C submitted to CDC within 90 days of case investigation start date
- A minimum of 90% of perinatal infant hepatitis C case reports are linked with a maternal report
- A minimum of 90% of case reports of chronic hepatitis B submitted to CDC within 90 days of case investigation start date

By December 31, were mother and child matches ascertained from h	ealth department Select one	
vital records by linking all known births from the prior calendar year	to mothers found Pes, all	
in your viral hepatitis surveillance data base?	□ Yes, some	
	□ No, none	
During this reporting period, what percent of your perinatal hepatitis	C case reports Number:	
were submitted to CDC within 90 days of case investigation start date	?? Total:	
	%:	
	□ Unknown	
During this reporting period, what percent of your perinatal hepatitis	C case reports Number:	
were linked with a maternal report?	Total:	
	%:	
	□ Unknown	
During this reporting period, what percent of your chronic hepatitis E	case reports Number:	
were submitted to CDC within 90 days of case investigation start date	?? Total:	
	%:	
	□ Unknown	

Measures 1.3.1.c, 1.3.2.b

- A minimum of 90% of case reports of perinatal hepatitis C submitted to CDC are complete for age, gender, race/ethnicity, county of residence
- A minimum of 90% of case reports of chronic hepatitis B submitted to CDC are complete for age, gender, race/ethnicity, county of residence

	Age	Gender	Race and/or ethnicity	County of residence
Perinatal hepatitis C	Number:	Number:	Number:	Number:
	Total:	Total:	Total:	Total:

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

	%:	%:	%:	%:
Chronic hepatitis B	Number:	Number:	Number:	Number:
	Total:	Total:	Total:	Total:
	%:	%:	%:	%:

Measure 1.3.3.a

• A minimum of 90% of case reports of chronic hepatitis B are included in a longitudinal surveillance registry, including longitudinal detectable and undetectable HBV DNA test results

Have you developed a longitudinal surveillance registry for	Select one	
chronic hepatitis B?	□ Completed	□ Not started
	□ In progress	
What percent of your chronic hepatitis B case reports are	Number:	□ Unknown
included in your registry?	Total:	□ N/A (registry not started)
	%:	
Does your registry include longitudinal detectable and	Select one	
undetectable HBV DNA test results for the chronic hepatitis B	□ Yes	□ N/A (registry not started)
cases?	□ No	

Measures 1.3.3.b - 1.3.3.c

- Jurisdiction reports data on hepatitis B continuum of care, consistent with CDC guidance
- Chronic hepatitis B data and hepatitis B continuum of care data are included in the annual summary of surveillance data

Are you reporting hepatitis B continuum of care data?	Select one	
	□ Yes	□ No
Does your annual viral hepatitis surveillance report include	Select one	
chronic hepatitis B data?	□ Yes	□ N/A (report not started)
	□ No	
Does your annual viral hepatitis surveillance report include	Select one	
hepatitis B continuum of care data?	□ Yes	□ N/A (report not started)
	□ No	

Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Use this space	
if needed	
ii fieeded	
to provide	
additional	
information	
related to	
Section 1.3	